Artemether-Lumefantrine Supplier and Exporter to Kenya

Malaria remains a major public health challenge in Kenya, particularly in the Lake Victoria basin, the coastal region, and other endemic zones. Artemisinin-based combination therapies such as Artemether-Lumefantrine are the recommended first-line treatment for uncomplicated malaria in Kenya, procured across the public health system, private pharmacies, and donor-supported programmes. Demand for quality-assured ACTs spans national tenders, importers, and the private retail market.

Pharmaceutical products imported into Kenya require registration with the Pharmacy and Poisons Board (PPB). We work with Kenyan importer and distributor partners to register Artemether-Lumefantrine for the Kenyan market, providing the CTD and ACTD dossiers PPB requires, with regulatory assistance through the process. If you are an established Kenyan importer looking to add a WHO-GMP ACT to your portfolio, we would like to hear from you.

We manufacture Artemether-Lumefantrine in 20/120 mg, 40/240 mg, and 80/480 mg strengths, in both standard and dispersible tablets for paediatric dosing, important given the malaria burden among young children in endemic counties. Packaging and labelling can be configured to the Kenyan market.

Once registered, Artemether-Lumefantrine can be supplied for Kenyan government malaria tenders, donor and NGO health programmes, and private-market distribution, with competitive volume pricing, flexible packaging, and private labelling.

MOQ and pricing depend on strength, formulation, packaging, and volume. We handle export logistics and documentation for shipments to Kenya through the regional supply hub at Mombasa. Request a quote with your requirements for exact terms.